Search results
Results from the WOW.Com Content Network
Valsartan, sold under the brand name Diovan among others, is a medication used to treat high blood pressure, heart failure, and diabetic kidney disease. [8] It belongs to a class of medications referred to as angiotensin II receptor blockers (ARBs).
Valsartan/hydrochlorothiazide, sold under the brand name Diovan HCT among others, is a medication used to treat high blood pressure when valsartan is not sufficient. [6] It is a combination of valsartan, an angiotensin receptor blocker with hydrochlorothiazide , a diuretic . [ 7 ]
Sacubitril/valsartan, sold under the brand name Entresto among others, is a fixed-dose combination medication for use in heart failure.It consists of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker valsartan.
At Novartis, patent expiration for blockbuster drugs Diovan and Zometa shaved more than $2 billion from the top line in 2013. Sales of blood pressure drug Diovan sank 20% and revenue from Zometa ...
Hydrochlorothiazide, sold under the brand name Hydrodiuril among others, is a diuretic medication used to treat hypertension and swelling due to fluid build-up. [4] Other uses include treating diabetes insipidus and renal tubular acidosis and to decrease the risk of kidney stones in those with a high calcium level in the urine. [4]
Most of the known actions of Ang II are mediated through the AT 1 receptors, for example vasoconstriction, aldosterone release, renal sodium reabsorption and vasopressin secretion. The AT 2 receptor also takes part in regulation of blood pressure and renal function but mediates antagonistic effects compared to the AT 1 receptor. [8] [10] [11] [12]
Verapamil, sold under various trade names, [1] is a calcium channel blocker medication used for the treatment of high blood pressure, angina (chest pain from not enough blood flow to the heart), and supraventricular tachycardia. [9]
There have been a significant number of publications since then, and a Food and Drug Administration panel [22] voted, with some controversy, 20:3 that available studies "supported a signal of harm", but voted 22:1 to keep the drug on the market. The meta-analysis was not supported by an interim analysis of the trial designed to evaluate the ...